Skip to Main Content

Author Details

Meenu Jain
Georgia Cancer Center, Augusta University
2011
25
17
PMIDPaper TitleJournal TitlePublished Year
33902424Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options.Endocr Metab Immune Disord Drug Targets2022
33902424Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options.Endocr Metab Immune Disord Drug Targets2022
27990624Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.Histol Histopathol2017
28609459HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model.PLoS One2017
29258180Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.Int J Mol Sci2017
29062041Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.Sci Rep2017
27990624Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.Histol Histopathol2017
28139732Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models.Sci Rep2017
28114280RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.Oncogene2017
28114280RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.Oncogene2017
28139732Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models.Sci Rep2017
29258180Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.Int J Mol Sci2017
29062041Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.Sci Rep2017
28609459HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model.PLoS One2017
27022280Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma.Onco Targets Ther2016
27022280Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma.Onco Targets Ther2016
27429653Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.Int J Cancer Res2016
27917327p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment.Biochem Physiol2016
28149704Cancer Therapeutics Following Newton's Third Law.Biochem Physiol2016
28149448Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.J Cancer Sci Ther2016
28149704Cancer Therapeutics Following Newton's Third Law.Biochem Physiol2016
28149448Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.J Cancer Sci Ther2016
27917327p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment.Biochem Physiol2016
27429653Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.Int J Cancer Res2016
25767039Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.Cancer Med2015
25767039Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.Cancer Med2015
27042399Vascular Mimicry: The Next Big Glioblastoma Target.Biochem Physiol2015
26618093When Seed and Soil Theory Meets Chicken or Egg Theory in Cancer Metastasis.Biochem Physiol2015
26446994Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.Nucleic Acids Res2015
26618093When Seed and Soil Theory Meets Chicken or Egg Theory in Cancer Metastasis.Biochem Physiol2015
26446994Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.Nucleic Acids Res2015
27042399Vascular Mimicry: The Next Big Glioblastoma Target.Biochem Physiol2015
24423307Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas.J Clin Endocrinol Metab2014
24423307Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas.J Clin Endocrinol Metab2014
25047265ZNF367 inhibits cancer progression and is targeted by miR-195.PLoS One2014
24781864miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3.Endocr Relat Cancer2014
25047265ZNF367 inhibits cancer progression and is targeted by miR-195.PLoS One2014
24781864miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3.Endocr Relat Cancer2014
23361940Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.Horm Cancer2013
24238045MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.Surgery2013
23361940Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.Horm Cancer2013
23533247TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.Endocr Relat Cancer2013
24238045MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.Surgery2013
23533247TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.Endocr Relat Cancer2013
22570059Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.Cancer2012
22504887Molecular markers of adrenocortical tumors.J Surg Oncol2012
22570059Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.Cancer2012
22504887Molecular markers of adrenocortical tumors.J Surg Oncol2012
22096502KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer.PLoS One2011
22096502KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer.PLoS One2011
  • 1 - 50 of 50

Recommended Authors

Jiayu Liang
institute of urology
Career Start Year 2016
Number of shared co-authors 0
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 1
Chad V Pecot
University of North Carolina at Chapel Hill
Career Start Year 2009
Number of shared co-authors 0
Xiaoyong Huang
Medical College, Yan'an University
Career Start Year 2007
Number of shared co-authors 0
Young K Song
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 6
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 0
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Career Start Year 2005
Number of shared co-authors 0
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
Fan Zhang
Huaihe Hospital of Henan University
Career Start Year 2004
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 2
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Wei Zhang
Children's Hospital, Zhejiang University School of Medicine
Career Start Year 2001
Number of shared co-authors 0
Limei Hu
Aier Eye Hospital of Wuhan University
Career Start Year 2001
Number of shared co-authors 0
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 0
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
Fan Yang
West China Second Hospital, Sichuan University
Career Start Year 2000
Number of shared co-authors 2
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year 1999
Number of shared co-authors 0
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 0
Erxi Wu
Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin
Career Start Year 1997
Number of shared co-authors 0
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 0
Dong Lin
Fujian Medical University Cancer Hospital and Fujian Cancer Hospital
Career Start Year 1996
Number of shared co-authors 0
Shi-Yuan Cheng
Northwestern University Feinberg School of Medicine
Career Start Year 1996
Number of shared co-authors 1
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 0
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 2
Paul N Span
Radboud University Medical Center
Career Start Year 1993
Number of shared co-authors 0
Anil K Sood
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 1
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 0
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 1
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 11
Adrian L Harris
University of Oxford
Career Start Year 1981
Number of shared co-authors 0

Collaborators

Electron Kebebew
Stanford University School of Medicine
Co-authored papers 12
Lisa Zhang
National Institute of Child Health and Development
Co-authored papers 10
Yi Liu-Chittenden
Department of Biochemistry and Howard Hughes Medical Institute, Stanford University
Co-authored papers 4
Myriem Boufraqech
The University of Texas at Austin
Co-authored papers 4
Dhaval Patel
National Cancer Institute, National Institutes of Health
Co-authored papers 4
Mei He
Sichuan University
Co-authored papers 4
Naris Nilubol
Center for Cancer Research
Co-authored papers 3
Sudheer Kumar Gara
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Yonghong Wang
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Maria J Merino
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Raj K Puri
Co-authored papers 2
Shubin Wang
The First Affiliated Hospital of Zhengzhou University
Co-authored papers 1
Tom Mikkelsen
Ontario Brain Institute
Co-authored papers 1
Karel Pacak
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Co-authored papers 1
Shweta Kotian
Center for Drug Evaluation and Research
Co-authored papers 1
Markku Miettinen
National Cancer Institute
Co-authored papers 1
Rachel Aufforth
The University of North Carolina
Co-authored papers 1
Michael J Demeure
Co-authored papers 1
Min Shen
National Center for Advancing Translational Sciences, National Institutes of Health
Co-authored papers 1
Susan R Davis
Co-authored papers 1
Ryan J Ellis
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Sean Davis
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 1
Samira M Sadowski
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Martha Quezado
National Cancer Institute (NCI), National Institutes of Health (NIH)
Co-authored papers 1
Xiaolin Wu
Leidos Biomedical Research Inc.
Co-authored papers 1
Kelli Gaskins
Frederick National Laboratory for Cancer Research, National Institutes of Health
Co-authored papers 1
Release 1.2